Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
This study has been completed.
Information provided by:
First received: October 4, 2006
Last updated: July 22, 2009
Last verified: July 2009
The purpose of this study is to see if GW876008 in Irritable Bowel Syndrome patients will reverse stress-induced hypersensitivity, by looking at thresholds for perception and pain.
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||A Phase IIa, Single-centre, Randomised, Placebo-controlled, Double-blind, Three-period Crossover Study Investigating the Effects on Gut Autonomic Responses of Single Administrations of Either 20 mg or 200 mg GW876008, a CRF1 Antagonist, to Adult Patients With Irritable Bowel Syndrome|
Further study details as provided by GlaxoSmithKline:
Primary Outcome Measures:
- Change in regional rectal mucosal blood flow in response to a cold water pressor test and in response to a listening test.
Secondary Outcome Measures:
- Thresholds for rectal pain sensitivity
|Study Start Date:||December 2006|
|Study Completion Date:||October 2007|
|Primary Completion Date:||October 2007 (Final data collection date for primary outcome measure)|
Other Name: GW876008
Contacts and Locations